PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of March 2, 2026, PODD stock price declined to $245.45 with 1,102,150 million shares trading.

PODD has a beta of 0.60, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.10 to the broad based SPY ETF.

PODD has a market cap of $17.27 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $784 million in Revenue and $1.55 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.08.

In the last 3 years, PODD traded as high as $354.88 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, IVV, SPY, VB.

PODD has underperformed the market in the last year with a return of -9.9%, while the SPY ETF gained +16.7%. In the last 3 month period, PODD fell short of the market, returning -20.6%, while SPY returned +1.0%. However, in the most recent 2 weeks PODD has outperformed the stock market by returning +1.1%, while SPY returned +0.7%.

PODD support price is $241.06 and resistance is $252.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.